SusanElaineBatesMD

Division of Hematology/Oncology, Columbia University Medical Center. Senior Investigator, Medical Oncology Branch and Affiliates, National Cancer Institute

Request Appointment

Overview of Dr. Bates

Dr. Susan Bates is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, NewYork-Presbyterian/Columbia University Irving Medical Center, and James J. Peters Veterans Affairs Medical Center. She received her medical degree from University of Arkansas for Medical Sciences (UAMS) College of Medicine and has been in practice 43 years. She is one of 378 doctors at New York-Presbyterian Hospital and one of 10 doctors at James J. Peters Veterans Affairs Medical Center who specialize in Oncology. She has more than 100 publications and over 500 citings.

Office
161 Fort Washington Ave.
Herbert Irving Pavilion, 9th floor
New York, NY 10032
Book by Phone+1(708) 571-0836

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1982 - 1984
University of Arkansas for Medical Sciences (UAMS) College of MedicineResidency, Internal Medicine, 1978 - 1980
University of Arkansas For Medical Sciences College of MedicineClass of 1978

Certifications & Licensure

NY State Medical License 2015 - 2026
NJ State Medical License 2022 - 2025
AR State Medical License 1978 - 2024
MD State Medical License 1985 - 2018
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Editor in Chief The Oncologist, 2022

Clinical Trials

Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma Start of enrollment: 2001 Mar 08
Completed
Phase 2
Depsipeptide in Treating Patients With Solid Tumors Start of enrollment: 1997 Aug 01
Completed
Phase 1
Monoclonal Antibody Plus Chemotherapy in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2 Start of enrollment: 1999 Aug 01
Completed
Phase 2
Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug Resistance Start of enrollment: 2000 Aug 09
Recruiting
Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer Start of enrollment: 2003 Sep 01
Completed
Phase 2
PET Imaging With Tc-94m Sestamibi to Assess Resistance to Chemotherapy Start of enrollment: 2004 May 16
Completed
Phase 2
Collection of Tissue Samples for Study of Multidrug Resistance Start of enrollment: 2003 Dec 19
Completed
Multidrug Resistance Proteins in Patients Enrolled in Clinical Trials Outside of the National Cancer Institute Center for Cancer Research Start of enrollment: 2005 Dec 01
A Phase 1, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612) in Advanced Malignancies Start of enrollment: 2009 Mar 25
Completed
Phase 1
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers Start of enrollment: 2009 Jul 01
Completed
Phase 1
GRN1005 for Brain Metastases From Breast or Lung Cancer Start of enrollment: 2012 Aug 29
Withdrawn
Phase 2
Join now to see all

Publications & Presentations

PubMed

588 citations
The Role of ABC Transporters in Clinical Practice
Gregory D. Leonard, Tito Fojo, Susan E. Bates
The Oncologist. 2003-10-01
4084 citations
Multidrug resistance in cancer: role of ATP–dependent transporters
Michael M. Gottesman, Tito Fojo, Susan E. Bates
Nature Reviews. Cancer. 2002-01-01
27 citations
Adjuvant and neoadjuvant cancer therapies: A historical review and a rational approach to understand outcomes.
Mauricio Burotto, Julia Wilkerson, Wilfred D. Stein, Susan E. Bates, Tito Fojo
Seminars in Oncology. 2019-02-01

Journal Articles

Clinical Trials in Pancreatic Cancer: A Long Slog
Susan Bates, MD, The Oncologist

Authored Content

Epidermal Growth Factor Receptor (EGFR) Inhibitor PD153035 Reverses ABCG2-Mediated Multidrug Resistance in Non-Small Cell Lung Cancer: In Vitro and in VivoMarch 2018

Press Mentions

ORIGINAL ARTICLE Bioengineered miR-27b-3p and miR-328-3p Modulate Drug Metabolism and Disposition via the Regulation of Target ADME Gene ExpressionMay 16th, 2019
Susan Bates, M.D., and Antonio “Tito” Fojo, M.D., Ph.D.: Thirty Years of Research, Discovery, Service, and Mentorship at the National Cancer InstituteNovember 4th, 2015

Grant Support

Translational Studies Of The Histone Deacetylase Inhibitor RomidepsinNational Cancer Institute2010–2011
Investigation Of The ABC Half-Transporter ABCG2National Cancer Institute2010–2011
Clinical Studies To Circumvent Drug ResistanceNational Cancer Institute2010–2011
Translational Studies Of The Histone Deacetylase Inhibitor RomidepsinDivision Of Basic Sciences - Nci2009
Investigation Of The ABC Half-Transporter ABCG2Division Of Basic Sciences - Nci2009
Clinical Studies To Circumvent Drug ResistanceDivision Of Basic Sciences - Nci2009
Translational Studies Of The Histone Deacetylase Inhibitor RomidepsinNational Cancer Institute2008
Investigation Of The ABC Half-Transporter ABCG2National Cancer Institute2008
Clinical Studies Of Multidrug Resistance ReversalNational Cancer Institute2007–2008
III. Investigation Of The ABC Half-Transporter ABCG2National Cancer Institute2007
II. Clinical And Laboratory Studies Of The Histone Deacetylase Inhibitor DepsipeNational Cancer Institute2007
Investigation Of The ABC Half-Transporter ABCG2Division Of Basic Sciences - Nci2006
Clinical And Laboratory Studies Of The Histone DeacetylaDivision Of Basic Sciences - Nci2006
Clinical Studies Of Multidrug Resistance ReversalDivision Of Basic Sciences - Nci2004–2006
II. Clinical And Laboratory Studies Of The Histone DeaceDivision Of Basic Sciences - Nci2005
III. Investigation Of The ABC Half-Transporter ABCG2Division Of Basic Sciences - Nci2004–2005
Histone Deacetylase Inhibitor DepsipeptideDivision Of Basic Sciences - Nci2004